Apellis Pharmaceuticals (APLS) Competitors

Apellis Pharmaceuticals (NASDAQ:APLS) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Does the media prefer APLS or BPMC?

In the previous week, Blueprint Medicines had 5 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 7 mentions for Blueprint Medicines and 2 mentions for Apellis Pharmaceuticals. Blueprint Medicines' average media sentiment score of 1.34 beat Apellis Pharmaceuticals' score of 0.93 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, APLS or BPMC?

Blueprint Medicines has lower revenue, but higher earnings than Apellis Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$781.37M	2.80	-$197.88M	-$1.79	-9.74
Blueprint Medicines	$508.82M	16.26	-$67.09M	-$2.47	-51.87

Do insiders and institutionals hold more shares of APLS or BPMC?

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is APLS or BPMC more profitable?

Blueprint Medicines has a net margin of -27.70% compared to Apellis Pharmaceuticals' net margin of -28.83%. Blueprint Medicines' return on equity of -64.60% beat Apellis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	-28.83%	-99.19%	-25.35%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Which has more risk and volatility, APLS or BPMC?

Apellis Pharmaceuticals has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Do analysts prefer APLS or BPMC?

Apellis Pharmaceuticals presently has a consensus price target of $40.05, suggesting a potential upside of 129.79%. Blueprint Medicines has a consensus price target of $128.06, suggesting a potential downside of 0.04%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.62
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.27

Summary

Apellis Pharmaceuticals and Blueprint Medicines tied by winning 8 of the 16 factors compared between the two stocks.